DYN
Dyne Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.00B
P/E Ratio
—
EPS
$-3.47
Beta
1.28
52W High
$25.00
52W Low
$8.06
50-Day MA
$17.68
200-Day MA
$16.38
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.19
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-466.14M |
| Operating Margin | 0.00% |
| Return on Equity | -55.70% |
| Return on Assets | -31.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.89 |
| Price-to-Book | 3.07 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -8.87 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $165.22M |
| Float | $156.19M |
| % Insiders | 0.31% |
| % Institutions | 114.31% |
Historical Volatility
HV 10-Day
39.44%
HV 20-Day
49.11%
HV 30-Day
52.22%
HV 60-Day
71.72%
HV Rank
9.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($38.19 target)
3
Strong Buy11
Buy2
HoldData last updated: 4/29/2026